GlassScriptPhysician profile
Katherine A Bean
NPI 1295346856
$7,224.24
in general payments reported to CMS, 2019-2025
29 companies · $2,306 in 2025
The $2,306 reported for 2025 was more than what 96% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $324 · 2022: $1,671 · 2023: $1,077 · 2024: $1,845 · 2025: $2,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,228.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,237.56 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,114.31 | 2021-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $718.35 | 2022-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $675.56 | 2021-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $628.54 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $292.38 | 2022-2025 | Dupixent |
| Pfizer INC. | $265.28 | 2021-2025 | |
| Madrigal Pharmaceuticals | $212.39 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $129.72 | 2022-2024 | |
| Janssen Scientific Affairs, LLC | $93.39 | 2024 | Tremfya |
| Qol Medical, LLC | $92.11 | 2023 | Sucraid |
| Organon LLC | $90.57 | 2021-2024 | Renflexis, Hadlima |
| Merck Sharp & Dohme LLC | $89.50 | 2021-2024 | Dificid, Zinplava |
| Lilly USA, LLC | $78.12 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $77.14 | 2024-2025 | Ibsrela |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $69.95 | 2022 | |
| Intercept Pharmaceuticals, INC. | $62.62 | 2021-2025 | Ocaliva |
| Braintree Laboratories, INC. | $41.78 | 2022-2025 | Suflave |
| Celgene Corporation | $40.72 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $39.82 | 2024-2025 | Voquezna |
| Amgen INC. | $31.90 | 2022 | |
| Boston Scientific Corporation | $28.27 | 2022-2023 | Watchman Access System |
| Albireo Pharma, INC. | $21.83 | 2024 | Iqirvo |
| Alfasigma USA, INC. | $18.36 | 2022 | |
| Acacia Pharma INC | $17.04 | 2021 | |
| Echosens North America, INC. | $16.14 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.46 | 2023 | Cyltezo |
| Medtronic, INC. | $13.52 | 2021 | |
| Dynavax Technologies Corporation | $11.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Bean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.